Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FinFMT-IBS: FMT for IBS Food Intolerance
NCT05361785Recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of allogeneic fecal microbiota in irritable bowel syndrome (IBS) (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: The effect of FMT for tolerance of FODMAPs in the IBS patients' diet. Started Apr 2022; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05361785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361785.